In the 1990s, tumour necrosis factor-α inhibitor therapy ushered in the biologic therapy era
for inflammatory bowel disease, leading to marked improvements in treatment options and …

Typically, therapeutic proteins (TPs) have a low risk for eliciting meaningful drug interactions
(DIs). However, there are select instances where TP drug interactions (TP‐DIs) of clinical …

Inflammatory bowel disease is a chronic disease with variable degrees of extent, severity,
and activity. A proportion of patients will have disease that is refractory to licensed therapies …

Background The expanding options in advanced therapies for ulcerative colitis (UC) and
Crohn's disease (CD) present challenges in treatment selection. Persistence analysis …

ABSTRACT Introduction In recent decades, Rheumatoid arthritis (RA) treatment landscape
has evolved with the induction of new biological and targeted therapies that provide …

Autoimmune rheumatic diseases are a cluster of heterogeneous disorders that share some
clinical symptoms such as pain, tissue damage, immune deregulation, and the presence of …

Abstract Background and Objective Whether benefits and risks of intravenous (IV) infliximab
combotherapy with immunosuppressants versus infliximab monotherapy apply to …

Abstract The coronavirus disease 2019 (COVID-19) pandemic has prompted significant
changes in patient care in rheumatology and gastroenterology, with clinical guidance issued …

Abstract Purpose of Review An overview of how the treatment landscape of axial
spondyloarthritis (axSpA) has shaped our understanding of the disease. Recent Findings …

Context: Oral manifestations that arose from COVID-19 infection often causes morbidity and
systemic drug administration is less effective. Roselle flower (Hibiscus sabdariffa) is one of …